
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results
Silexion Therapeutics (Nasdaq: SLXN) shares surge over 72% on Phase 2/3 SIL204 trial progress for KRAS-driven pancreatic cancer and Q1 2026 results.

Silexion Therapeutics (Nasdaq: SLXN) shares surge over 72% on Phase 2/3 SIL204 trial progress for KRAS-driven pancreatic cancer and Q1 2026 results.
On Telegram · @iinewswire
Get stock alerts on Telegram
Daily news, podcast drops, and featured-company updates as they post.

Rising Treasury yields and a stronger US dollar pressure stocks as investors weigh inflation risks, AI leadership and weakening market breadth.
May 18, 2026

deVere Group CEO Nigel Green warns global investors that the Trump-Xi summit produced optics rather than resolution, with rare earths, semiconductors, tariffs and Taiwan all left unaddressed.
May 15, 2026

HCW Biologics (NASDAQ: HCWB) shares surge on Q1 2026 results: revenue up 493% to $6.5M driven by a worldwide HCW11-006 license to Beijing Trimmune, plus an equity stake and progress on the HCW9302 alopecia areata trial.
May 15, 2026

ProShares UltraShort Silver (NYSE: ZSL) and Direxion Daily Junior Gold Miners Bear 2X (NYSE: JDST) topped NYSE percentage gainers as silver prices and junior mining stocks sold off sharply.
May 15, 2026

Texas is the new center of US AI infrastructure, creating structural industrial gas demand as DFW data centers and the Stargate AI buildout rapidly scale.
May 14, 2026

The AI buildout is driving structural nitrogen demand that outpaces supply in North America, squeezing mid-market industrial buyers in Canada and the US.
May 14, 2026

May 20, 2026
May 19, 2026
May 15, 2026
May 14, 2026